-
1.发明申请公开(公告)号：US20080125477A1
公开(公告)日：2008-05-29
申请号：US11748897
申请日：2007-05-15
申请人： Jasbir Singh , Matt Shaoming Duan , Thorsteinn Thorsteinsson , Mitchell B. Friedman , Mark Gurney
发明人： Jasbir Singh , Matt Shaoming Duan , Thorsteinn Thorsteinsson , Mitchell B. Friedman , Mark Gurney
CPC分类号： A61K9/4866 , A61K9/14 , A61K9/2013 , A61K9/2031 , A61K9/2054 , A61K9/2095 , A61K9/4858 , A61K31/404
摘要： The present invention is directed to pharmaceutical compositions of 7-(acryloyl)indoles, such as 4,5 -Dichloro-thiophene-2-sulfonic acid [(E)-3-[1-(2,4-dichlorophenylmethyl)-5-fluoro-3-methyl-1H-indol-7-yl]-acryloyl]amide (DTSI), having a structure shown below. The invention is also directed to methods of treatment utilizing formulations of the DTSI and processes of preparation of the formulations.
摘要翻译： 本发明涉及7-（丙烯酰基）吲哚的药物组合物，例如4,5-二氯 - 噻吩-2-磺酸[（E）-3- [1-（2,4-二氯苯基甲基）-5- 氟-3-甲基-1H-吲哚-7-基] - 丙烯酰基]酰胺（DTSI），具有下面所示的结构。 本发明还涉及使用DTSI制剂的治疗方法和制剂的制备方法。
-
2.发明申请BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION 失效LTA4H用于治疗炎症的BIARYL取代的杂合物抑制剂公开(公告)号：US20070066820A1
公开(公告)日：2007-03-22
申请号：US11426287
申请日：2006-06-23
申请人： Vincent Sandanayaka , Jasbir Singh , Mark Gurney , Bjorn Mamat , Peng Yu , Louis Bedel , Lei Zhao
发明人： Vincent Sandanayaka , Jasbir Singh , Mark Gurney , Bjorn Mamat , Peng Yu , Louis Bedel , Lei Zhao
IPC分类号： C07D417/02 , C07D413/02 , C07D403/02
CPC分类号： C07D403/12 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D207/263 , C07D207/46 , C07D211/22 , C07D241/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/12
摘要： The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders. The compounds have general formula Ψ: An example is
摘要翻译： 本发明涉及可用于治疗和预防和预防炎性疾病和病症的LTA4H（白三烯A4水解酶）的联芳基取代的杂环抑制剂的化学属。 化合物具有通式Psi：一个例子
-
3.发明申请Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment 审中-公开心肌梗塞，中风和PAOD的易感基因，治疗方法公开(公告)号：US20060019269A1
公开(公告)日：2006-01-26
申请号：US11096191
申请日：2005-03-30
IPC分类号： C12Q1/68 , A61K31/401 , A61K31/366 , A61K31/225
CPC分类号： A61K31/225 , A61K31/366 , A61K31/401 , A61K38/00 , C07K14/4705 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a stating and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.
摘要翻译： 公开了心肌梗塞（MI）和染色体13q12上的位点的连锁。 特别地，通过遗传关联分析将该基因内的FLAP基因显示为MI和ACS以及中风和PAOD的易感基因。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供包含白三烯合成抑制剂的组合物和使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者的C-反应蛋白的说明和方法。
-
4.发明申请Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association 审中-公开基于单倍型关联的哮喘和其他呼吸系统疾病的诊断和治疗方法公开(公告)号：US20060014165A1
公开(公告)日：2006-01-19
申请号：US11043752
申请日：2005-01-26
申请人： Hakon Hakonarson , Mark Gurney , Eva Halapi
发明人： Hakon Hakonarson , Mark Gurney , Eva Halapi
CPC分类号： C12Q1/6883 , A61K31/47 , A61K31/519 , A61K31/553 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： Methods for diagnosis of asthma or a susceptibility to asthma based on detection of at-risk haplotypes associated with MAP3K9 are disclosed. Also methods for treatment of asthma or a susceptibility to asthma based on detection of at-risk haplotypes associated with MAP3K9 are disclosed. In particular, pathway targeting for treating individuals who are at-risk of developing asmtha are described. In certain aspects, MLK1 inhibitors are used in treatment methods.
摘要翻译： 公开了基于检测与MAP3K9相关的风险单倍型的哮喘诊断或哮喘易感性的方法。 公开了基于检测与MAP3K9相关的风险单倍型的哮喘治疗或哮喘易感性的方法。 特别地，描述了用于治疗处于发展asmtha风险的个体的途径靶向。 在某些方面，MLK1抑制剂用于治疗方法。
-
公开(公告)号：US20050288314A1
公开(公告)日：2005-12-29
申请号：US11147127
申请日：2005-06-07
申请人： Jasbir Singh , Mark Gurney
发明人： Jasbir Singh , Mark Gurney
IPC分类号： C07D239/95 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , A61K31/517 , C07D43/02
CPC分类号： C07D239/95 , C07D401/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12
摘要： 2,4-Diaminoquinazolines of formulae I-IV and VI are useful for treating spinal muscular atrophy (SMA).
摘要翻译： 式I-IV和VI的2,4-二氨基喹唑啉可用于治疗脊髓性肌萎缩（SMA）。
-
6.发明申请Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment 失效心肌梗塞，中风和PAOD的易感基因; 治疗方法公开(公告)号：US20050113408A1
公开(公告)日：2005-05-26
申请号：US10830477
申请日：2004-04-22
CPC分类号： C12Q1/6883 , A61K38/00 , C07K14/4705 , C12Q2600/156 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.
摘要翻译： 公开了心肌梗塞（MI）和染色体13q12上的位点的连锁。 特别地，通过遗传关联分析将该基因内的FLAP基因显示为MI和ACS以及中风和PAOD的易感基因。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。
-
公开(公告)号：US20050096457A1
公开(公告)日：2005-05-05
申请号：US10801493
申请日：2004-03-16
申请人： Riqiang Yan , Alfredo Tomasselli , Mark Gurney , Thomas Emmons , Michael Bienkowski , Robert Heinrikson
发明人： Riqiang Yan , Alfredo Tomasselli , Mark Gurney , Thomas Emmons , Michael Bienkowski , Robert Heinrikson
IPC分类号： G01N33/50 , A61K45/00 , A61P25/28 , A61P43/00 , C07K2/00 , C07K5/00 , C07K5/103 , C07K7/06 , C07K7/08 , C07K14/47 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12Q1/02 , C12Q1/37 , G01N33/15
CPC分类号： C07K14/4711 , C07K5/1013 , C07K7/06 , C07K7/08 , C07K14/4702 , C12Q1/37 , G01N2333/96425 , G01N2500/02
摘要： The present invention is directed to novel substrates for Hu-Asp. More particularly, the invention provides peptide substrates and fusion polypeptide substrates comprising a β-secretase cleavage site. Methods and compositions for making and using the peptides are disclosed.
摘要翻译： 本发明涉及用于Hu-Asp的新型底物。 更具体地，本发明提供了包含β-分泌酶切割位点的肽底物和融合多肽底物。 公开了制备和使用肽的方法和组合物。
-
8.发明申请公开(公告)号：US20050080232A1
公开(公告)日：2005-04-14
申请号：US10477076
申请日：2001-05-09
申请人： Mark Gurney , Michael Bienkowski , Robert Heinrikson , Luis Parodi , Riqiang Yan
发明人： Mark Gurney , Michael Bienkowski , Robert Heinrikson , Luis Parodi , Riqiang Yan
CPC分类号： C12N9/6478 , C07K14/4711 , C07K2319/00 , C12N2799/026 , C12Q1/37 , G01N2333/96472
摘要： The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
摘要翻译： 本发明提供用于切割APP蛋白和相关核酸，肽，载体，细胞和细胞分离物和测定的β分泌酶切割位点的酶和酶程序。 本发明还提供了修饰的APP蛋白和相关核酸，肽，载体，细胞和细胞分离物以及特别可用于鉴定用于治疗或预防阿尔茨海默病的候选治疗剂的测定。
-
9.发明授权Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation 失效用于治疗炎症的LTA4H的二芳基取代的杂环抑制剂公开(公告)号：US08598359B2
公开(公告)日：2013-12-03
申请号：US12136874
申请日：2008-06-11
申请人： Vincent Sandanayaka , Jasbir Singh , Mark Gurney , Bjorn Mamat , Peng Yu , Louis Bedell , Lei Zhao , Rama K. Mishra
发明人： Vincent Sandanayaka , Jasbir Singh , Mark Gurney , Bjorn Mamat , Peng Yu , Louis Bedell , Lei Zhao , Rama K. Mishra
IPC分类号： C07D211/20 , A61K31/445
CPC分类号： C07D403/12 , C07D207/08 , C07D207/09 , C07D207/12 , C07D207/26 , C07D207/263 , C07D207/46 , C07D211/22 , C07D241/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/06 , C07D413/12 , C07D417/12
摘要： The present invention relates to a chemical genus of biaryl substituted heterocycle inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders. The compounds have general formula Ψ: An example is
摘要翻译： 本发明涉及可用于治疗和预防和预防炎性疾病和病症的LTA4H（白三烯A4水解酶）的联芳基取代的杂环抑制剂的化学属。 化合物具有通式Psi：一个例子
-
公开(公告)号：US20090042900A1
公开(公告)日：2009-02-12
申请号：US11832255
申请日：2007-08-01
申请人： Jasbir Singh , Mark Gurney
发明人： Jasbir Singh , Mark Gurney
IPC分类号： A61K31/517 , A61P19/00 , C07D239/84 , C07D401/14
CPC分类号： C07D239/95 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14
摘要： 2,4-Diaminoquinazolines of formula (I) are provided herein and are useful for treating spinal muscular atrophy (SMA).
摘要翻译： 本文提供式（I）的2,4-二氨基喹唑啉，可用于治疗脊髓性肌萎缩（SMA）。
-
-
-
-
-
-
-
-
-
搜索结果
38 条记录 (耗时 0.064 秒)
